Tumor News and Research

RSS

Naviscan launches PEM breast cancer scanner in Europe

Naviscan, Inc., announces the European launch of the Naviscan Positron Emission Mammography scanner at two prestigious radiology conferences in Vienna.

3 Mar 2011

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Work led by St. Jude Children's Research Hospital investigators provides fresh insight into mechanisms controlling programmed cell death pathways and offers new targets in the fight against cancer and virus-infected cells

3 Mar 2011

Protein serum amyloid A could be a potential diagnostic biomarker for lung cancer

Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease - difficult to diagnose in its earliest and most treatable stages - and to develop drugs that stop lung cancer from spreading. Their study appears in ACS's Journal of Proteome Research.

3 Mar 2011

Breast Health Center receives three-year accreditation from NAPBC

The Breast Health Center at Women & Infants Hospital of Rhode Island recently earned a three-year accreditation from the National Accreditation Program for Breast Centers.

3 Mar 2011

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Robotic surgery offers the same or better results than minimally invasive laparoscopic procedures for treating kidney disease, and can potentially help more patients because it is not as difficult for surgeons to learn, according to a new study led by Henry Ford Hospital specialists.

2 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

Robotic surgery offers favourable outcomes in patients with kidney disease

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

IRX Therapeutics, a developer of immune therapies to make cancer treatments better, announced today it has signed a research collaboration agreement with one of the world's leading research-based pharmaceutical companies.

1 Mar 2011

Combined diagnosis and treatment of tumors: photothermically activated ultrasound contrast agent

Diagnosis and treatment form the basis of modern medicine. Traditionally, they are two separate steps; however, it doesn’t have to be that way. The term “theranostic” refers to the combination of a diagnostic test with a specific treatment based on the result of the test. This integrated approach should be particularly helpful in providing more targeted treatment for cancer patients.

1 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Heterotaxin useful for studying intestinal birth defects may also inhibit cancerous tumor growth

In an interesting bit of scientific serendipity, researchers at North Carolina State University have found that a chemical compound useful for studying the origins of intestinal birth defects may also inhibit the growth and spread of cancerous tumors.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

Sudden cessation of smoking may be symptom of lung cancer

Many longtime smokers quit spontaneously with little effort shortly before their lung cancer is diagnosed, leading some researchers to speculate that sudden cessation may be a symptom of lung cancer.

1 Mar 2011

Cancer drug may help combat flu

Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

Western Medical installs Toshiba's vascular X-ray system to provide efficiency during diagnostic procedures

To increase diagnostic capabilities and provide patients with the highest quality care, Western Medical Center Santa Ana has installed Toshiba America Medical Systems, Inc.'s Infinix VF-i bi-plane vascular X-ray system with Volume Navigation 3D roadmapping.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Tumor News and Research

Naviscan launches PEM breast cancer scanner in Europe

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Protein serum amyloid A could be a potential diagnostic biomarker for lung cancer

Breast Health Center receives three-year accreditation from NAPBC

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

Robotic surgery offers favourable outcomes in patients with kidney disease

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

Combined diagnosis and treatment of tumors: photothermically activated ultrasound contrast agent

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Heterotaxin useful for studying intestinal birth defects may also inhibit cancerous tumor growth

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

Sudden cessation of smoking may be symptom of lung cancer

Cancer drug may help combat flu

TCD announces first patient treated in its TCD-717 Phase I trial

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Western Medical installs Toshiba's vascular X-ray system to provide efficiency during diagnostic procedures

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News